SEARCH:   Advanced

Blood, 5 November 2009, Vol. 114, No. 19, pp. 4293-4299. Prepublished online as a Blood First Edition Paper on August 25, 2009; DOI 10.1182/blood-2009-05-220525. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2009-05-220525v1 114/19/4293    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Verneris, M. R. Articles by Wagner, J. E. PubMed PubMed Citation Articles by Verneris, M. R. Articles by Wagner, J. E. Related Collections Transplantation Free Research Articles Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units Michael R. Verneris1,2, Claudio G. Brunstein2,3, Juliet Barker2,3, Margaret L. MacMillan1,2, Todd DeFor1,2, David H. McKenna4, Michael J. Burke1, Bruce R. Blazar1,2, Jeffrey S. Miller2,3, Philip B. McGlave2,3, Daniel J. Weisdorf2,3, and John E. Wagner1,2 1 Department of Pediatrics, 2 Blood and Marrow Transplant Program, 3 Department of Medicine, and 4 Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis Umbilical cord blood (UCB) transplantation is potentially curative for acute leukemia. This analysis was performed to identify risk factors associated with leukemia relapse following myeloablative UCB transplantation. Acute leukemia patients (n = 177; 88 with acute lymphoblastic leukemia and 89 with acute myeloid leukemia) were treated at a single center. Patients received a UCB graft composed of either 1 (47%) or 2 (53%) partially human leukocyte antigen (HLA)–matched unit(s). Conditioning was with cyclophosphamide and total body irradiation with or without fludarabine. The incidence of relapse was 26% (95% confidence interval [CI], 19%-33%). In multivariate analysis, relapse was higher in advanced disease patients ( third complete remission [CR3]; relative risk [RR], 3.6; P < .01), with a trend toward less relapse in recipients of 2 UCB units (RR = 0.6; P = .07). However, relapse was lower for CR1-2 patients who received 2 UCB units (RR 0.5; P < .03). Leukemia-free survival was 40% (95% CI, 30%-51%) and 51% (95% CI, 41%-62%) for single- and double-unit recipients, respectively (P = .35). Although it is known that transplantation in CR1 and CR2 is associated with less relapse risk, this analysis reveals an enhanced graft-versus-leukemia effect in acute leukemia patients after transplantation with 2 partially HLA-matched UCB units. This trial was registered at http://clinicaltrials.gov as NCT00309842 [ClinicalTrials.gov] . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Are 2 cords better than 1? Meghan Delaney Blood 2009 114: 3980-3981. [Full Text] [PDF] This article has been cited by other articles: M. Delaney Are 2 cords better than 1? Blood, November 5, 2009; 114(19): 3980 - 3981. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020